Montelukast VersaFilm™ is an early stage pipeline opportunity that leverages the VersaFilm™ technology for the treatment of degenerative diseases of the brain, such as mild cognitive impairment and Alzheimer's disease, the most prominent form of dementia.
IntelGenx is working to repurpose montelukast as a therapeutic to treat neurodegenerative diseases by re-formulating the drug into an oral film-based product. Montelukast has been approved by the U.S. Food and Drug Administration in 1997 for the treatment of asthma and seasonal allergic rhinitis.
IntelGenx ' proprietary VersaFilm™ technology is especially suited for special needs patient populations, and Montelukast VersaFilm™product therefore offers many distinct advantages over tablets for Alzheimer’s Disease patients, including the avoidance and minimization of first-pass-effects, ease of administration, improved API bioavailability, lower dosing and toxicity, better acceptability and improved compliance.
IntelGenx has begun preparation for a phase II-a proof-of-concept study.
Based on the outcome of this first efficacy trial in humans, IntelGenx will be actively seeking a partnership or alliance opportunity to further advance developmental work and commercialization of Montelukast VersaFilm™.